Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances
S Iseas, G Mariano, L Gros, N Baba-Hamed… - Molecular Diagnosis & …, 2024 - Springer
Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal malignancy associated with
high-risk human papillomavirus (HPV) and is currently one of the fastest-growing causes of …
high-risk human papillomavirus (HPV) and is currently one of the fastest-growing causes of …
Biomarkers in anal cancer: current status in diagnosis, disease progression and therapeutic strategies
MC Mathias-Machado, RDA Peixoto, CMV Moniz… - Biomedicines, 2022 - mdpi.com
Squamous cell carcinoma of the anal canal (SCCA) is a rare neoplasm, but with rising
incidence rates in the past few decades; it is etiologically linked with the human …
incidence rates in the past few decades; it is etiologically linked with the human …
The emerging role of immunotherapy in the treatment of anal cancer
R Saúde-Conde, A Parisi, EF Giunta, M Meyers… - Current Opinion in …, 2022 - Elsevier
For decades, chemoradiotherapy for early-stage disease and systemic chemotherapy for
advanced disease have represented the mainstay of treatment for anal cancer. Over the last …
advanced disease have represented the mainstay of treatment for anal cancer. Over the last …
Metastatic or locally recurrent anal squamous cell carcinoma (SCAC): current clinical trial landscape and novel approaches
JE Rogers, M Leung, B Johnson - Cancer Management and …, 2022 - Taylor & Francis
Anal squamous cell carcinoma (SCAC) is a human papillomavirus (HPV) driven malignancy.
Given inadequate HPV-vaccination rates, SCAC will continue to be a public health concern …
Given inadequate HPV-vaccination rates, SCAC will continue to be a public health concern …
Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial
A Debernardi, A Meurisse, JL Prétet, D Guenat… - Frontiers in …, 2022 - frontiersin.org
Squamous Cell Carcinoma of the Anal canal (SCCA) is a rare disease associated with a
Human Papillomavirus (HPV) infection in most cases, predominantly the HPV16 genotype …
Human Papillomavirus (HPV) infection in most cases, predominantly the HPV16 genotype …
RNA-seq analysis identifies transcriptomic profiles associated with anal cancer recurrence among people living with HIV
Y Ye, KJ Maroney, HW Wiener, OA Mamaeva… - Annals of …, 2023 - Taylor & Francis
Background Chemoradiation therapy (CRT) is the standard of care for squamous cell
carcinoma of the anus (SCCA), the most common type of anal cancer. However …
carcinoma of the anus (SCCA), the most common type of anal cancer. However …
Transcriptome and microbiome-immune changes across preinvasive and invasive anal cancer lesions
Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal malignancy linked 26 to
high-risk Human papillomavirus (HPV) infection, which develops from 27 precursor lesions …
high-risk Human papillomavirus (HPV) infection, which develops from 27 precursor lesions …
Systemic therapies for advanced squamous cell anal cancer
F Sclafani, S Rao - Current oncology reports, 2018 - Springer
Abstract Purpose of Review We aim to summarise the available evidence on systemic
therapies for advanced anal cancer. Recent Findings There is no universal consensus on …
therapies for advanced anal cancer. Recent Findings There is no universal consensus on …
Research on anal squamous cell carcinoma: systemic therapy strategies for anal cancer
Simple Summary Anal cancer is rare with an estimated 9000 new cases predicted to occur
in the United States in 2021. However, rates of new anal cancer cases and deaths from the …
in the United States in 2021. However, rates of new anal cancer cases and deaths from the …
Interaction between IGF2‐PI3K axis and cancer‐associated‐fibroblasts promotes anal squamous carcinogenesis
W Cacheux, A Lièvre, S Richon… - … Journal of Cancer, 2019 - Wiley Online Library
Anal squamous cell carcinoma (ASCC) is a rare tumour, but its incidence is increasing.
Standard chemoradiotherapy fails to cure 20% of patients and no targeted therapy is …
Standard chemoradiotherapy fails to cure 20% of patients and no targeted therapy is …